Daily Dose: Delay Before Start of Triple Therapy Raises Risk for COPD Exacerbations


Patient Care brings primary care clinicians a lot of medical news every day—it’s easy to miss an important study. The Daily Dose provides a concise summary of one of the website's leading stories you may not have seen.

On October 21, 2022, we reviewed a study presented at the American College of Chest Physicians (CHEST) 2022 Annual Meeting, that assessed whether prompt initiation of triple therapy (TT) following a second moderate exacerbation within 12 months was associated with a lower risk of subsequent COPD exacerbations.

The study

There were 17 988 adults aged ≥40 years with a diagnosis of COPD included in the study. Patients were stratified into 3 groups based on timing of a TT prescription after the index exacerbation:

  • Prompt within 30 days (25.6%)

  • Delayed 31-180 days (42.7%)

  • Very delayed 181+ days (31.7%)

The results

Proportion of patients who had ≥1 exacerbations by length of TT initiation delay:

  • Prompt: 66.6%

  • Delayed: 81.3%

  • Very delayed: 88.5% (p<.01)

Clinical implications

"Delays in starting triple therapy may introduce avoidable risks of future exacerbations including hospitalizations. These results support a more proactive approach to the management of COPD following moderate exacerbation events, particularly initiation of triple therapy," concluded researchers.

Click here for the full study review.

Related Videos
Tezepelumab Significantly Reduced Exacerbations in Patients with Severe Asthma, Respiratory Comorbidities
Related Content
© 2023 MJH Life Sciences

All rights reserved.